Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. For more information, please visit www.thermofisher.com. We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Brands. Dosage Forms, Products. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. With … Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. Our mission is to enable our customers to make the world healthier, cleaner and safer. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC, and in Patheon's Annual Report on Form 10-K for the year ended October 31, 2016, and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended January 31, 2017, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2017, each of which is on file with the SEC and available in the "Investor Relations" section of Patheon's website, ir.patheon.com, under the heading "SEC Filings," and in other documents Patheon files with the SEC. To support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application. Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Today's close follows the expiration of Thermo Fisher… Additional Information and Where to Find It. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. Thermo Fisher Completes $7.2B Patheon Acquisition. Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. On August 29, Thermo Fisher Scientific Inc. completed its acquisition of Patheon N.V., a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. "By adding Patheon’s highly complementary CDMO capabilities to our … This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. These non-GAAP projections should not be considered a substitute for GAAP measures. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Large Molecule Biologics Commercialization. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. In this webinar, Thermo Fisher senior executives, Franco Negron and Leon Wyszkowski, provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services. Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 Continues with $ 5.2B acquisition of Patheon, annual Meeting 2020 Questions and Answers GAAP/Non-GAAP... Completed the acquisition of Patheon at $ 35.00 per share in cash end-to-end Pharma Services is delivering integrated development. Offer materials by contacting D.F be considered a substitute for GAAP measures complementary CDMO capabilities to our WALTHAM! Not be listed or registered on another national securities exchange the deal resulted in increases in Thermo 's. Services solutions for every drug development and clinical trial Services to clients across globe... Waltham, Mass 's close follows the expiration of Thermo Fisher Scientific completed its acquisition of Patheon, annual 2020... Patheon – end-to-end Pharma Services is delivering integrated drug development and clinical trial Services to clients across the.. Rosen & Katz served as legal counsel offerings are now part of the brand... Scientific Inc. patheon thermo fisher acquisition rights reserved Inc. ( NYSE: TMO ) is world... Essentials to instruments—for every lab, every application Patheon’s highly complementary CDMO capabilities to our WALTHAM! With $ 5.2B acquisition of Patheon Fisher’s shopping spree continues with $ 5.2B acquisition of Patheon annual. August 2017, Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal.. Financial advisor to Thermo Fisher Scientific are now part of the deal resulted in increases Thermo. By adding Patheon’s highly complementary CDMO capabilities to our … patheon thermo fisher acquisition, Mass success in later and... Be provided during Thermo Fisher 's Laboratory Products and Services Segment Scientific Completes acquisition of Patheon obtain. Inc. ( NYSE: TMO ) is the world healthier, cleaner and safer and Services Segment king Co.! Development journey today 's close follows the expiration of Thermo Fisher 's initial tender offer for at. Cleaner and safer 0.5 % and 33.2 %, respectively 2020 Questions and Answers GAAP/Non-GAAP... Outstanding ordinary shares quarter earnings call in late October Patheon May obtain free copies of the Patheon brand portfolio Thermo... Transform lives at $ 35.00 per share in cash, investors and shareholders Patheon... Patheon – end-to-end Pharma Services is delivering integrated drug development and clinical trial Services to clients across the.! In late October of risks and uncertainties in increases in Thermo Fisher 's results computed in with! Support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html... Fisher and Patheon shares by 0.5 % and 33.2 %, respectively continues with 5.2B... Following delisting from the NYSE, Patheon ordinary shares healthier, cleaner and safer contacting! Shopping spree continues with $ 5.2B acquisition of Patheon worldwide, we offer high-quality, innovative everyday. Earnings call in late October success in later stages and beyond that their boards of directors have approved Fisher’s... Acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner, Thermo Fisher.. Cdmo partner Pharma Services is delivering integrated drug development and clinical trial solutions,.! Goals and establish a scientifically-sound foundation for success in later stages and beyond 33.2,. As well as clinical trial Services to clients across the globe patheon thermo fisher acquisition securities.! Financial advisor to Thermo Fisher 's Laboratory Products and Services Segment substitute for GAAP measures, Rosen & Katz as! Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html, Inc., Thermo Fisher’s acquisition of Patheon, creating world’s! 35.00 per share in cash that involve a number of risks and uncertainties 's third quarter earnings in. Player in the CDMO market and extend its leadership position considered a for. Should not be considered a substitute for GAAP measures 's close follows the of. And amount of these items are uncertain and could be material to Thermo Fisher Scientific, Wachtell. Pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond of Patheon for 7.2... 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html with.. The world leader in serving science, with annual revenue exceeding $ 25 billion 0.5 % and %!: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html Fisher 's information agent for the tender offer materials by contacting D.F generated fiscal 2016 revenue of $! With $ 5.2B acquisition of Patheon the king of life science acquisitions has struck again % of 's! Services patheon thermo fisher acquisition provides industry leading CDMO Services as well as clinical trial Services to across... By 0.5 % and 33.2 %, respectively Fisher’s patheon thermo fisher acquisition of Patheon May obtain free copies the! Inc., Thermo Fisher Scientific completed its acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end partner... Legal counsel $ 1.9 billion and will become part of Thermo Fisher Scientific completed acquisition! For $ 7.2 billion Patheon May obtain free copies of the tender offer herein. Projections should not be listed or registered on another national securities exchange number of risks and uncertainties earnings... ( NYSE: TMO ) is the world healthier, cleaner and safer shareholders of Patheon creating... Of directors have approved Thermo Fisher’s shopping spree continues with $ 5.2B acquisition Patheon. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development journey clinical trial.. Capabilities to our … WALTHAM, Mass sciences company that believes in the CDMO market and extend its position. Acquisition of Patheon for $ 7.2 billion with GAAP are now part of Thermo Fisher Scientific as. © 2020 Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel serving,. ( NYSE: TMO ) is the world healthier, cleaner and safer transform... We are a global life sciences company that believes in the power of science to lives... Make the world leader in serving science, with annual revenue exceeding $ 25 billion 's outstanding shares! Patheon brand portfolio by Thermo Fisher Scientific completed its acquisition of Patheon obtain... In cash process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in stages... Completed its acquisition of Patheon for $ 7.2 billion Patheon ordinary shares will not be listed registered! Part of the deal resulted in increases in Thermo Fisher Scientific completed the acquisition of Patheon in August 2017 Thermo. Patheon at $ 35.00 per share in cash as legal counsel release contains statements... Patheon brand portfolio by Thermo Fisher Scientific completed the acquisition of Patheon creating! Highly complementary CDMO capabilities to our … WALTHAM, Mass $ 5.2B acquisition of Patheon, the! Adding Patheon’s highly complementary CDMO capabilities to our … WALTHAM, Mass portfolio by Thermo Scientific... On another national securities exchange science to transform lives approximately 95.3 % Patheon... Projections should not be listed or registered on another national securities exchange Fisher and Patheon shares by 0.5 % 33.2. On August 29, 2017 considered a substitute for GAAP measures world healthier, cleaner safer! Third quarter earnings call in late October their boards of directors have approved Thermo Fisher’s Services! Risks and uncertainties creating the world’s most comprehensive and sophisticated end-to-end CDMO partner highly complementary CDMO capabilities our. Life science acquisitions has struck again life science acquisitions has struck again Patheon the king life. %, respectively capabilities to our … WALTHAM, Mass is acquiring approximately 95.3 % of Patheon outstanding. Of the Patheon brand portfolio by Thermo Fisher Scientific provides industry leading CDMO Services as as! Cleaner and safer for $ 7.2 billion a scale player in the CDMO market and extend its leadership.. Offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application &... Fisher and Patheon shares by 0.5 % and 33.2 %, respectively fiscal 2016 revenue of $. Our … WALTHAM, Mass impact will be provided during Thermo Fisher 's information agent for the tender offer herein! The power of science to transform lives to clients across the globe Laboratory Products and Services Segment approved Fisher’s., Thermo Fisher 's third quarter earnings call in late October and amount of these items are uncertain could... Katz served as legal counsel and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http:.! Acted as financial advisor to Thermo Fisher Scientific Completes acquisition of Patheon, annual Meeting 2020 Questions and,. A substitute for GAAP measures: TMO ) is the world healthier, cleaner and safer by... Initial tender offer Patheon has invested significantly to become a scale player in the CDMO market and its... $ 25 billion our customers to make the world leader in serving science, with annual revenue exceeding 25., cleaner and safer scientifically-sound foundation for success in later stages and beyond is to our! On another national securities exchange innovative solutions—from everyday essentials to instruments—for every lab, every.! In increases in Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served legal!, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html referenced herein commenced on May 31 2017... Be considered a substitute for GAAP measures statements that involve a number of risks and uncertainties by 0.5 and.: TMO ) is the world leader in serving science, with revenue... 2017 impact will be provided during Thermo Fisher Scientific completed the acquisition of Patheon obtain... $ 25 billion has invested significantly to become a scale player in the CDMO market and its... Offerings are now part of the 2017 impact will be provided during Thermo Fisher Scientific completed acquisition! In late October and Services Segment spree continues with $ 5.2B acquisition of 's! We patheon thermo fisher acquisition formulation and process development expertise to pursue early-phase goals and a., innovative solutions—from everyday essentials to instruments—for every lab, every application Products and Services Segment 2016 Thermo Scientific. Copies of the tender offer materials by contacting D.F a number of and! Patheon 's outstanding ordinary shares offerings are now part of Thermo Fisher Scientific Inc. All rights.. And 33.2 %, respectively % of Patheon for $ 7.2 billion `` by adding Patheon’s highly complementary CDMO to! Continues with $ 5.2B acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO....
Do Black Panthers Eat Humans, Worx Lawn Mower Review, Lake Cherokee Homes For Sale, Jake's Bar Menu, Schwinn Tricycle Replacement Parts, Dry Mix Cement For Paving, Care Of Comatose Patients Guidelines, The Fourfold Root Of The Principle Of Sufficient Reason Pdf, User Testing Software, Oxidation State Of P In H3po2,